Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
作者信息
Barochia Amisha V, Cui Xizhong, Natanson Charles, Eichacker Peter Q
出版信息
Crit Care Med. 2010 Jan;38(1):306-8. doi: 10.1097/CCM.0b013e3181b77fe3.
Abstract
摘要
相似文献
1
Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.死亡风险与依替多酸四钠（E5564）的疗效：脓毒症抗炎药物临床试验的设计考量
Crit Care Med. 2010 Jan;38(1):306-8. doi: 10.1097/CCM.0b013e3181b77fe3.
2
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.依洛珠单抗四钠（E5564）治疗严重脓毒症患者的 2 期临床试验。
Crit Care Med. 2010 Jan;38(1):72-83. doi: 10.1097/CCM.0b013e3181b07b78.
3
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.在严重脓毒症临床研究中，缺乏依据疾病严重程度相互作用进行定性治疗的证据。
Crit Care. 2005;9(6):R607-22. doi: 10.1186/cc3795. Epub 2005 Sep 22.
4
The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis.白蛋白作为脓毒症患者复苏液的作用：系统评价和荟萃分析。
Crit Care Med. 2011 Feb;39(2):386-91. doi: 10.1097/CCM.0b013e3181ffe217.
5
Antithrombin III for critically ill patients.用于重症患者的抗凝血酶III
Cochrane Database Syst Rev. 2016 Feb 8;2(2):CD005370. doi: 10.1002/14651858.CD005370.pub3.
6
Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients.与标准护理相比，自动监测用于危重症患者脓毒症的早期检测
Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD012404. doi: 10.1002/14651858.CD012404.pub2.
7
Pulmonary artery catheters for adult patients in intensive care.用于重症监护成年患者的肺动脉导管。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD003408. doi: 10.1002/14651858.CD003408.pub3.
8
Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial.甲磺酸萘莫司他治疗脓毒症的疗效与安全性（EASNMS）：一项多中心随机对照试验的研究方案
Trials. 2025 Jul 29;26(1):262. doi: 10.1186/s13063-025-08979-4.
9
REDuced CARBohydrate enteral nutrition compared to standard care in hyperglycaemic critically ill patients: A randomised phase II clinical trial (REDCARB).与标准治疗相比，减少碳水化合物的肠内营养用于高血糖重症患者：一项随机II期临床试验（REDCARB）
Clin Nutr ESPEN. 2025 Aug;68:368-374. doi: 10.1016/j.clnesp.2025.05.029. Epub 2025 May 23.
10
Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials.危重症患者基线死亡率风险对治疗效果的异质性：三项最近的脓毒症和 ARDS 随机对照试验的再分析。
Crit Care. 2019 May 3;23(1):156. doi: 10.1186/s13054-019-2446-1.
引用本文的文献
1
Unraveling immunosenescence in sepsis: from cellular mechanisms to therapeutics.解析脓毒症中的免疫衰老：从细胞机制到治疗方法
Cell Death Dis. 2025 May 16;16(1):393. doi: 10.1038/s41419-025-07714-w.
2
Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure.丹参（丹参）限制急性心肌梗死后心力衰竭中 MD2/TLR4-MyD88 复合物的形成和信号转导。
J Cell Mol Med. 2020 Sep;24(18):10677-10692. doi: 10.1111/jcmm.15688. Epub 2020 Aug 5.
3
TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.在小鼠腹部脓毒症的治疗环境中，TLR4抑制会损害细菌清除。
Inflamm Res. 2014 Nov;63(11):927-33. doi: 10.1007/s00011-014-0766-9. Epub 2014 Aug 15.
4
Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties.鉴定来源于中药虎杖的化合物虎杖苷 B 为一种选择性 Toll 样受体拮抗剂，具有很强的抗炎特性。
J Biol Chem. 2011 Jul 29;286(30):26470-9. doi: 10.1074/jbc.M111.227934. Epub 2011 Jun 10.
5
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.依利罗坦四钠（E5564）治疗脓毒症：临床前和临床研究综述。
Expert Opin Drug Metab Toxicol. 2011 Apr;7(4):479-94. doi: 10.1517/17425255.2011.558190. Epub 2011 Feb 17.
本文引用的文献
1
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.依洛珠单抗四钠（E5564）治疗严重脓毒症患者的 2 期临床试验。
Crit Care Med. 2010 Jan;38(1):72-83. doi: 10.1097/CCM.0b013e3181b07b78.
2
Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.皮质类固醇治疗成人严重脓毒症和脓毒性休克：一项系统评价
JAMA. 2009 Jun 10;301(22):2362-75. doi: 10.1001/jama.2009.815.
3
The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.脓毒症期间使用类固醇的效果取决于剂量和疾病严重程度：一项更新的荟萃分析。
Clin Microbiol Infect. 2009 Apr;15(4):308-18. doi: 10.1111/j.1469-0691.2009.02752.x.
4
Drotrecogin alfa (activated): real-life use and outcomes for the UK.重组人活化蛋白C（Drotrecogin alfa）：英国的实际应用及结果
Crit Care. 2008;12(2):R58. doi: 10.1186/cc6879. Epub 2008 Apr 22.
5
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.重组活化蛋白C：从临床试验到临床实践的推广
Eur J Anaesthesiol. 2008 Mar;25(3):211-6. doi: 10.1017/S0265021507002992. Epub 2007 Nov 22.
6
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.重组人活化蛋白C用于严重脓毒症且死亡风险较低的成人患者。
N Engl J Med. 2005 Sep 29;353(13):1332-41. doi: 10.1056/NEJMoa050935.
7
TLR4 antagonists for endotoxemia and beyond.用于治疗内毒素血症及其他病症的Toll样受体4拮抗剂。
Curr Opin Investig Drugs. 2005 May;6(5):496-502.
8
The efficacy of drotrecogin alfa depends on severity of illness.重组人活化蛋白C的疗效取决于疾病的严重程度。
Crit Care Med. 2004 Nov;32(11):2347. doi: 10.1097/01.ccm.0000146002.38054.70.
9
Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model.脓毒症的严重程度会改变大鼠脓毒症模型中对超氧阴离子抑制的效果。
J Appl Physiol (1985). 2004 Oct;97(4):1349-57. doi: 10.1152/japplphysiol.01161.2003. Epub 2004 May 28.
10
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.新型Toll样受体4导向的内毒素拮抗剂e5564对内毒素反应的抑制作用
J Pharmacol Exp Ther. 2003 Mar;304(3):1093-102. doi: 10.1124/jpet.102.044487.
Zotero 插件